A Case of Xanthoma Disseminatum in a Progressive Form With Bladder Involvement Effectively Treated With 2-Chlorodeoxyadenosine

Akdaş, Elçin; Beksaç, Burcu; Adışen, Esra; Erdem, Özlem; Öztaş, Murat Orhan

doi:10.5826/dpc.1302a124

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 6 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus far, cladribine use for XD has been described in 23 patients across 10 case reports and three case series [3][4][5][6]8,[11][12][13][14][15][16][17][18]. On review, patients were largely treated with 3-10 cycles of cladribine at a standard dose of 0.14 mg/kg/day for five days per month, with the exception of one pediatric patient [3] dosed according to body surface area.…”

Section: Discussionmentioning

confidence: 99%

Cladribine Use in Xanthoma Disseminatum: A Rare Case Presentation and Brief Updated Literature Review

Gayed,

Jew,

Al-Rohil

et al. 2024

Cureus

View full text Add to dashboard Cite

Xanthoma disseminatum (XD) is a rare, non-Langerhans cell histiocytosis. While treatment is notoriously difficult, 2-chlorodeoxyadenosine (cladribine) has recently emerged as a potential effective therapeutic option. Here, we describe the case of a 65-year-old male with XD who experienced significant cutaneous improvement after cladribine treatment. We also provide an updated literature review on cladribine use in patients with XD in light of reported adverse effects (AEs). While the efficacy of cladribine in XD is clear, no consensus exists for treatment duration and AE management. Hence, we strongly encourage interdisciplinary discourse involving dermatology and oncology in these cases.

show abstract